Stock ASLN ASLAN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
2.38 USD +5.87% Intraday chart for ASLAN Pharmaceuticals Limited -2.62% -43.02%
Jul. 03 Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Jul. 02 Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
AQ
ASLAN PHARMACEUTICALS : ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE Form 6 K
PU
ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K
PU
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
AQ
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
ASLAN Pharmaceuticals : 1Q2024 Financial Release
PU
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
AQ
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
AQ
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
AQ
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
AQ
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024
AQ
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
AQ
ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K
PU
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
AQ
ASLAN PHARMACEUTICALS : ANNOUNCES RECEIPT OF NASDAQ NOTICE - Form 6-K
PU
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and provides corporate update
AQ
ASLAN Pharmaceuticals : AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM - Form 6-K
PU
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
ASLAN PHARMACEUTICALS : REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Form 6-K
PU
ASLAN Pharmaceuticals : H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ASLN Stock
  4. News ASLAN Pharmaceuticals Limited
  5. Press Releases